Business Of Biotech cover image

Inhalable mRNA with Ethris' Carsten Rudolph, Ph.D.

Business Of Biotech

CHAPTER

Addressing Risks and Opportunities in Developing Pulmonary Drugs

Discussion on the potential risks and factors that could hinder progress in the development of pulmonary drugs, with a focus on targeting Primary Ciliary Dyskinesia (PCD) through mRNA delivery for a persistent effect.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner